Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Stock Report

Market Cap: US$103.2b

Regeneron Pharmaceuticals Future Growth

Future criteria checks 1/6

Regeneron Pharmaceuticals is forecast to grow earnings and revenue by 9.5% and 6.9% per annum respectively. EPS is expected to grow by 8.9% per annum. Return on equity is forecast to be 15.1% in 3 years.

Key information

9.5%

Earnings growth rate

8.9%

EPS growth rate

Biotechs earnings growth20.3%
Revenue growth rate6.9%
Future return on equity15.1%
Analyst coverage

Good

Last updated18 Mar 2024

Recent future growth updates

No updates

Recent updates

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16
Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Feb 02

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Oct 25
Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 52% Above Its Share Price

Aug 07
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 52% Above Its Share Price

Regeneron Pharmaceuticals (NASDAQ:REGN) Has A Pretty Healthy Balance Sheet

Jul 17
Regeneron Pharmaceuticals (NASDAQ:REGN) Has A Pretty Healthy Balance Sheet

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Apr 17
Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 46% Above Its Share Price

Feb 03
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 46% Above Its Share Price

Earnings and Revenue Growth Forecasts

NasdaqGS:REGN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202615,8885,0245,4765,81819
12/31/202514,8734,5634,7255,26825
12/31/202413,8864,1644,4985,16125
12/31/202313,1173,9543,6684,594N/A
9/30/202313,0973,9914,3595,224N/A
6/30/202312,6714,2993,0044,739N/A
3/31/202312,3704,1832,5274,281N/A
12/31/202212,1734,3383,3985,015N/A
9/30/202213,7105,3704,1485,668N/A
6/30/202214,2275,6877,8698,452N/A
3/31/202216,5087,9347,9368,515N/A
12/31/202116,0728,0756,5297,081N/A
9/30/202113,5436,9965,3815,940N/A
6/30/202112,3846,2051,6942,272N/A
3/31/20219,1984,0042,0292,589N/A
12/31/20208,4973,5132,0042,618N/A
9/30/20207,9383,1561,5822,175N/A
6/30/20207,3872,9842,4252,986N/A
3/31/20207,0132,2791,7062,231N/A
12/31/20196,5582,1162,0002,430N/A
9/30/20196,6222,1441,9952,371N/A
6/30/20196,5422,0691,9062,267N/A
3/31/20196,5722,4282,0952,473N/A
12/31/20185,1462,4441,8122,195N/A
9/30/20186,3651,7981,6282,033N/A
6/30/20186,2031,5911,6361,995N/A
3/31/20186,0651,4281,2681,570N/A
12/31/20175,8721,1991,0351,307N/A
9/30/20175,5171,278N/A1,118N/A
6/30/20175,2361,155N/A1,354N/A
3/31/20174,979963N/A1,784N/A
12/31/20164,860896N/A1,486N/A
9/30/20164,732797N/A1,377N/A
6/30/20164,649743N/A1,619N/A
3/31/20164,435741N/A1,477N/A
12/31/20154,104636N/A1,331N/A
9/30/20153,808571N/A1,247N/A
6/30/20153,396444N/A519N/A
3/31/20153,063346N/A597N/A
12/31/20142,820338N/A752N/A
9/30/20142,628345N/A831N/A
6/30/20142,499403N/A759N/A
3/31/20142,291394N/A551N/A
12/31/20132,105414N/A589N/A
9/30/20131,909798N/A400N/A
6/30/20131,740848N/A305N/A
3/31/20131,586837N/A99N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: REGN's forecast earnings growth (9.5% per year) is above the savings rate (2.3%).

Earnings vs Market: REGN's earnings (9.5% per year) are forecast to grow slower than the US market (13.3% per year).

High Growth Earnings: REGN's earnings are forecast to grow, but not significantly.

Revenue vs Market: REGN's revenue (6.9% per year) is forecast to grow slower than the US market (8.1% per year).

High Growth Revenue: REGN's revenue (6.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: REGN's Return on Equity is forecast to be low in 3 years time (15.1%).


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.